Geode Capital Management’s NeuroSense Therapeutics NRSN Stock Holding History

Geode Capital Management’s Portfolio NRSN Stock Details NRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-794	Closed	-$11.4K	–	4479
2026 Q2	$11.4K	Hold	794	–	–	﹤0.01%	4412
2026 Q1	$12K	Hold	794	–	–	﹤0.01%	4483
2025 Q4	$12.2K	Hold	794	–	–	﹤0.01%	4422
2025 Q3	$19.8K	Hold	794	–	–	﹤0.01%	4418
2025 Q2	$30K	Hold	794	–	–	﹤0.01%	4306
2025 Q1	$14.6K	Hold	794	–	–	﹤0.01%	4404
2024 Q4	$19K	Buy	794 +196	+33%	+$4.51K	﹤0.01%	4391
2024 Q3	$15.2K	Hold	598	–	–	﹤0.01%	4426
2024 Q2	$13.4K	Hold	598	–	–	﹤0.01%	4516
2024 Q1	$21.8K	Hold	598	–	–	﹤0.01%	4473
2023 Q4	$9.39K	Buy	+598	New	+$7.95K	﹤0.01%	4596

Other funds holding NRSN

PNC Financial Services Group Pittsburgh, Pennsylvania $191B AUM 30.51% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Geode Capital Management's NRSN Position: Q3 2026 in Review

Geode Capital Management sold out of NeuroSense Therapeutics (NRSN) in Q3 2026, closing a stake of 794 shares — an estimated $11.4K sold.

Geode Capital Management first reported a position in NRSN in Q4 2023 and held it in 11 quarters. The position peaked at $30K in Q2 2025. 4 funds tracked by Wall St. Rank hold NRSN as of Q3 2026.

Geode Capital Management reported no remaining NeuroSense Therapeutics position as of Q3 2026 after selling out during the quarter.
Geode Capital Management sold 794 NeuroSense Therapeutics shares in Q3 2026, an estimated $11.4K.
Geode Capital Management first reported a position in NeuroSense Therapeutics in Q4 2023 and held it in 11 quarters.
Geode Capital Management's NeuroSense Therapeutics position peaked at $30K in Q2 2025.
4 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q3 2026.

Based on Geode Capital Management's 13F filing for Q3 2026, filed 6 Nov 2026.